FDA Grants Rare Pediatric Disease Designation to REGENXBIO's RGX-121 Gene Therapy for the Treatment of Mucopolysaccharidosis Type II (MPS II)
August 02, 2016 08:00 ET
|
REGENXBIO Inc.
ROCKVILLE, Md., Aug. 02, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant...
REGENXBIO to Host Conference Call on August 9 to Discuss Second Quarter 2016 Financial Results and Recent Operational Highlights
August 01, 2016 16:01 ET
|
REGENXBIO Inc.
ROCKVILLE, Md., Aug. 01, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant...
REGENXBIO Provides Update on Lead Gene Therapy Development Programs
July 05, 2016 16:01 ET
|
REGENXBIO Inc.
Phase I/II clinical trial of RGX-501 for the treatment of homozygous familial hypercholesterolemia is actively recruiting and screening patients; expect to enroll first patient in second half of...
REGENXBIO and Biogen Enter Exclusive License Agreement for the Development of Gene Therapy Treatments for Rare Genetic Vision Disorders
May 16, 2016 07:00 ET
|
REGENXBIO Inc.
ROCKVILLE, Md., May 16, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant...
REGENXBIO Reports First Quarter 2016 Financial Results and Recent Operational Highlights
May 05, 2016 08:00 ET
|
REGENXBIO Inc.
On track to initiate a Phase I/II clinical trial for RGX-501 for the treatment of homozygous familial hypercholesterolemia in the first half of 2016Progressing toward filing an IND with the U.S....
REGENXBIO to Participate in May Investor Conferences
May 03, 2016 08:00 ET
|
REGENXBIO Inc.
ROCKVILLE, Md., May 03, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant...
Preclinical Data from REGENXBIO’s RGX-314 and RGX-121 Gene Therapy Programs to be Presented at the American Society of Gene & Cell Therapy 19th Annual Meeting
April 19, 2016 08:00 ET
|
REGENXBIO Inc.
High expression of anti-VEGF antibody achieved in rhesus macaques with administration of RGX-314 for treatment of wet age-related macular degenerationGene transfer mediated by RGX-121 shown to...
REGENXBIO Reports Fourth Quarter and Full-Year 2015 Financial Results and Recent Operational Progress
March 03, 2016 08:00 ET
|
REGENXBIO Inc.
Entered 2016 in strong financial position with more than $215 million in cash, cash equivalents and marketable securities; on track to advance multiple lead gene therapy product candidate programs...
REGENXBIO Announces Appointment of Faraz Ali as Chief Business Officer
March 01, 2016 08:00 ET
|
REGENXBIO Inc.
ROCKVILLE, Md., March 01, 2016 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant...
REGENXBIO Provides Year-End 2015 Corporate Update
January 07, 2016 08:00 ET
|
REGENXBIO Inc.
Company begins 2016 in strong financial position, on track to advance multiple lead gene therapy product candidate programs into clinicRGX-501 IND for treatment of homozygous familial...